CNTA — Centessa Pharmaceuticals plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1847903 ·
Last close
$40.50
Market Cap
$6.27B
52W High
$40.50
52W Low
$40.50
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -79,773,000 | -79,241,000 | 641,763,000 | 62,431,000 | 154,415,000 |
| Dec 2025 | 0 | — | -68,472,000 | -66,163,000 | 687,495,000 | 61,299,000 | 160,632,000 |
| Sep 2025 | 0 | — | -53,790,000 | -54,891,000 | 448,300,000 | 50,811,000 | 146,726,000 |
| Jun 2025 | 0 | — | -54,653,000 | -50,343,000 | 492,127,000 | 44,242,000 | 147,208,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-193,817,000
Investing CF
$-418,531,000
Financing CF
$291,528,000
CapEx
$-245,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.83
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,186,234,000
Inventory
—
Receivables
$60,341,000
ST Investments
$233,281,000
EBIT TTM
$-184,254,000
Pretax Income TTM
$-195,713,000
Interest Exp TTM
$11,459,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-256,344,992
Free Cash Flow
$-128,715,624
Enterprise Value
$6,108,489,216
Total Cash
$276,588,992
Total Debt
$118,555,000
Shares Out
154,731,309
Trailing EPS
$-1.78
Book Value
$3.15
ROE
-57.4%
ROA
-27.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 15,000,000 | -207,692,000 | -197,532,000 | 687,495,000 | 160,632,000 | — | -193,817,000 |
| Dec 2024 | 0 | -201,055,000 | -235,757,000 | 576,798,000 | 175,253,000 | — | -142,055,000 |
| Dec 2023 | 6,853,000 | -171,283,000 | -151,085,000 | 360,246,000 | 124,002,000 | — | -160,342,000 |
| Dec 2022 | 0 | -210,283,000 | -216,207,000 | 444,307,000 | 108,138,000 | — | -200,546,000 |
TTM Snapshot
Revenues TTM
$1,031,000
NetIncome TTM
$-135,918,000
OpCashFlow TTM
$0
Assets (Latest)
$576,798,000
Forward EPS
$-1.78
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LGND | LIGAND PHARMACEUTICALS INC | $6.34B | $316.24 | — |
| BLTE | BELITE BIO, INC | $5.99B | $149.33 | — |
| COGT | Cogent Biosciences, Inc. | $6.64B | $38.87 | — |
| XENE | Xenon Pharmaceuticals Inc. | $6.66B | $68.92 | — |
| ERAS | Erasca, Inc. | $5.76B | $18.53 | — |
News headlines (Yahoo Finance, 1h cache)
Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?
2026-06-29 07:55 · Yahoo
Eli Lilly (LLY) Acquires Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonists
2026-06-26 08:06 · Yahoo
Sector Update: Healthcare Stocks Advance Late Afternoon
2026-06-24 19:32 · Yahoo
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
2026-06-24 12:45 · Yahoo
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
2026-06-22 20:05 · Yahoo
Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years
2026-05-08 11:16 · Yahoo
Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions
2026-05-06 15:35 · Yahoo
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?
2026-05-03 19:12 · Yahoo
Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals
2026-04-29 16:03 · Yahoo
Is This $6.3 Billion Deal a Game Changer for Eli Lilly?
2026-04-16 13:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.